Skip to content
drillr.ai

BEAM

Beam Therapeutics Inc.

NASDAQ · USHealthcareBiotechnology
$26.33-4.36%

Price as of Jul 20, 2026

BEAM news

Beam Therapeutics Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

    CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (https://www.globenewswire.com/Tracker?data=LODiFa7-iD4ho-z_jOSlPx-tgJNtZKEr5T1N3MiCYKsbHbWUqeYYF6tx8yJ4ToQRvx-CE9lPjbdXIiDytHD_IJeWqLP0a8BzpMBntK4stks=) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific dis

    Globe Newswire ·

  2. Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

    Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026 The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C., May 13, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Beam Therapeutics as an inaugural industry sponsor. The support fur

    PR Newswire ·

  3. Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

    CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (https://www.globenewswire.com/Tracker?data=7lNR8R1PWPAqUSA882jXfxMYWJzLqO9IiJbsVE-MafwCjkmVE0pMESK2pUaE5nK2qL74zlK0vBSp96DFnymP-Lz7Eh_AK15QhHRKKdMs1Jg=) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disea

    Globe Newswire ·

  4. Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

    Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution of Red Blood Cell Dysfunction and Reduced Time in Hospital Driven by a Median of One Cell Collection Cycle and Rapid Engraftment U.S. Biologics License Application (BLA) Submission for risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., April 01, 202

    Globe Newswire ·